EPIRUS Biopharmaceuticals Inc represents values of innovation, integrity, and dedication to patient well-being. As a leading biopharmaceutical company, EPIRUS is committed to developing high-quality, affordable medicines to improve people's lives. The company's corporate philosophy revolves around scientific excellence, collaboration, and a patient-centric approach. EPIRUS strives to deliver exceptional healthcare solutions by leveraging advanced technologies and strategic partnerships. With a focus on disease areas with unmet medical needs, EPIRUS aims to make a meaningful impact on global healthcare by providing accessible and effective treatments.

EPIRUS Biopharmaceuticals Inc primarily operates in the United States.

EPIRUS Biopharmaceuticals Inc has achieved several significant milestones in its journey. Firstly, the company successfully developed and launched its biosimilar products, catering to a wide range of therapeutic areas. Additionally, EPIRUS received regulatory approvals from various health authorities, enabling widespread market access for their innovative medications. The company also formed strategic partnerships and collaborations with leading players in the pharmaceutical industry, strengthening its position and extending its global reach. EPIRUS Biopharmaceuticals Inc's unwavering commitment to scientific research and development has resulted in groundbreaking advancements, making them a prominent player in the biopharmaceutical sector.

EPIRUS Biopharmaceuticals Inc., a leading biotechnology company, has a rich history and background. Founded in 2011, EPIRUS focuses on developing biosimilar and highly similar biologic drugs to provide affordable treatment options for various diseases. The company combines innovative science with extensive expertise to bring high-quality medicines to patients worldwide. EPIRUS has a diverse pipeline of biosimilars and novel biologic assets, covering critical therapeutic areas such as immunology, oncology, and inflammatory diseases. With a commitment to improving healthcare accessibility, EPIRUS has positioned itself as a trusted and dedicated player in the biopharmaceutical industry, catering to the needs of patients and healthcare professionals alike.

The main competitors of EPIRUS Biopharmaceuticals Inc in the market include other biopharmaceutical companies such as Amgen Inc, Genentech, GlaxoSmithKline plc, Novartis AG, and Pfizer Inc. These companies also venture into the development and production of innovative and generic biopharmaceutical products, aiming to address various diseases and medical conditions. EPIRUS Biopharmaceuticals Inc competes with these industry players through its unique product offerings, research and development initiatives, pricing strategies, and market positioning.

EPIRUS Biopharmaceuticals Inc primarily operates in the biopharmaceutical industry.

The business model of EPIRUS Biopharmaceuticals Inc revolves around the development and commercialization of biosimilar products. As a company focused on the biopharmaceutical industry, EPIRUS aims to offer more affordable alternatives to existing biologic drugs, providing greater access to patients in need. By utilizing their expertise in bioprocess engineering and advanced manufacturing technologies, EPIRUS strives to create high-quality biosimilars that are therapeutically equivalent to reference products. Through strategic partnerships and collaborations, EPIRUS seeks to effectively navigate regulatory processes and gain market approval for their biosimilar candidates. Ultimately, their business model aims to improve patient outcomes and reduce healthcare costs through the availability of cost-effective biologic therapies.

Az KGV a EPIRUS Biopharmaceuticals esetében jelenleg nem számítható ki.

A EPIRUS Biopharmaceuticals számára az aktuális KUV nem számítható ki.

Az AlleAktien Minőségi Score EPIRUS Biopharmaceuticals esetében 3/10.

A EPIRUS Biopharmaceuticals esetében jelenleg nem számítható ki az árbevétel.

A nyereséget jelenleg nem lehet kiszámítani a EPIRUS Biopharmaceuticals számára.

EPIRUS Biopharmaceuticals Inc. is an American biotechnology company that was founded in 2010. The company offers a wide range of biopharmaceuticals that can be used to treat various diseases. EPIRUS Biopharmaceuticals aims to develop innovative therapies and affordable drugs to improve patient outcomes and public health. The business model is based on three pillars: biologics, generics, and biosimilars. EPIRUS Biopharmaceuticals focuses on the development of biopharmaceuticals, including cancer treatments and drugs for rheumatoid arthritis and other inflammatory diseases. The company also manufactures and distributes generic drugs at more affordable prices. Additionally, EPIRUS Biopharmaceuticals specializes in producing biosimilars, which are biological drugs that act similarly to patented biopharmaceuticals. Overall, the company's goal is to improve public health by providing high-quality and affordable medications that enhance patient outcomes.

A(z) EPIRUS Biopharmaceuticals évente alkalommal oszt ki 0 USD összegű osztalékot.

A EPIRUS Biopharmaceuticals esetében jelenleg nem lehet kiszámítani a osztalékot, vagy a vállalat nem fizet osztalékot.

A(z) EPIRUS Biopharmaceuticals ISIN kódja: US29428P1075.

A EPIRUS Biopharmaceuticals WKN-je A117U3.

Az EPIRUS Biopharmaceuticals tőzsdei rövidítése EPRSQ.

Az elmúlt 12 hónapban a(z) EPIRUS Biopharmaceuticals osztalékot fizetett összegben. Ez körülbelül osztalékhozamnak felel meg. A következő 12 hóban a(z) EPIRUS Biopharmaceuticals várhatóan 0 USD összegű osztalékot fog fizetni.

A(z) EPIRUS Biopharmaceuticals jelenlegi osztalékhozama .

A(z) EPIRUS Biopharmaceuticals negyedévente fizet osztalékot. Az osztalékokat a következő hónapokban osztják ki: .

A EPIRUS Biopharmaceuticals az elmúlt 0 évben minden évben fizetett osztalékot.

A következő 12 hónapban 0 USD összegű osztalékra számítanak. Ez 0 % osztalékhozamnak felel meg.

A(z) EPIRUS Biopharmaceuticals a(z) 'Egészség' szektorhoz van besorolva.

Az utolsó, EPIRUS Biopharmaceuticals által 2024. 11. 01.-án/én fizetett 0 USD összegű osztalék megszerzéséhez a részvénynek az ex-nap előtti 2024. 11. 01.-nál kellett lennie a portfóliódban.

Az utolsó osztalék kifizetése 2024. 11. 01. időpontban történt.

2023 évben a EPIRUS Biopharmaceuticals 0 USD összegű osztalékot fizetett ki.

Az EPIRUS Biopharmaceuticals osztalékait USD fizeti ki.